Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety, Feasibility, and Preliminary Efficacy of Intratumoral Delivery of CA9-Targeted Chimeric Antigen Receptor Macrophage Therapy in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

NCT07865832 is registered in ClinicalTrials.gov with Liangyou Gu as lead sponsor.

NCT NCT07865832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07865832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety, Feasibility, and Preliminary Efficacy of Intratumoral Delivery of CA9-Targeted Chimeric Antigen Receptor Macrophage Therapy in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
Lead sponsor
Liangyou Gu
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
September 30, 2029
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma